ECSP22080846A - Variantes de anticuerpos caninos - Google Patents

Variantes de anticuerpos caninos

Info

Publication number
ECSP22080846A
ECSP22080846A ECSENADI202280846A ECDI202280846A ECSP22080846A EC SP22080846 A ECSP22080846 A EC SP22080846A EC SENADI202280846 A ECSENADI202280846 A EC SENADI202280846A EC DI202280846 A ECDI202280846 A EC DI202280846A EC SP22080846 A ECSP22080846 A EC SP22080846A
Authority
EC
Ecuador
Prior art keywords
variants
canine antibodies
canine
antibodies
canine antibody
Prior art date
Application number
ECSENADI202280846A
Other languages
English (en)
Inventor
Marie Bergeron Lisa
Luis CAMPOS Henry
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of ECSP22080846A publication Critical patent/ECSP22080846A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La invención se refiere generalmente a variantes de anticuerpos caninos y usos de estos. Específicamente, la invención se refiere a mutaciones en la región constante del anticuerpo canino para mejorar su semivida y otras características.
ECSENADI202280846A 2020-04-17 2022-10-17 Variantes de anticuerpos caninos ECSP22080846A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063011453P 2020-04-17 2020-04-17

Publications (1)

Publication Number Publication Date
ECSP22080846A true ECSP22080846A (es) 2023-02-28

Family

ID=75888187

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202280846A ECSP22080846A (es) 2020-04-17 2022-10-17 Variantes de anticuerpos caninos

Country Status (16)

Country Link
US (1) US20230242635A1 (es)
EP (1) EP4136106A1 (es)
JP (1) JP2023522029A (es)
KR (1) KR20230005156A (es)
CN (1) CN115996949A (es)
AU (1) AU2021256056A1 (es)
BR (1) BR112022020944A2 (es)
CA (1) CA3175921A1 (es)
CL (2) CL2022002857A1 (es)
CO (1) CO2022014695A2 (es)
EC (1) ECSP22080846A (es)
IL (1) IL297287A (es)
MX (1) MX2022012866A (es)
PE (1) PE20230108A1 (es)
TW (1) TW202204403A (es)
WO (1) WO2021212081A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
SG11202106478UA (en) 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2021231464A1 (en) 2020-05-11 2021-11-18 Invetx Inc. Compositions for increasing half-life of a therapeutic agent in canines and methods of use
BR112022027028A2 (pt) 2020-07-10 2023-03-07 Invetx Inc Composições para aumentar a meia-vida de um agente terapêutico em felinos e métodos de uso
CA3194936A1 (en) * 2020-09-28 2022-03-31 Zoetis Services Llc Canine antibody variants
WO2023250284A2 (en) * 2022-06-21 2023-12-28 Zoetis Services Llc Canine antibody mutants

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
EP2332985A3 (en) 2004-11-12 2012-01-25 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2011291462A1 (en) 2010-08-19 2013-03-14 Zoetis Belgium S.A. Anti-NGF antibodies and their use
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
US11053308B2 (en) * 2016-08-05 2021-07-06 Chugai Seiyaku Kabushiki Kaisha Method for treating IL-8-related diseases
US20200181258A1 (en) * 2016-10-17 2020-06-11 Vetoquinol Sa Modified antibody constant region
MX2021004313A (es) * 2018-10-18 2021-05-27 Kindred Biosciences Inc Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario.
SG11202106478UA (en) * 2019-01-03 2021-07-29 Invetx Inc Compositions for increasing half-life of a therapeutic agent in canines and methods of use
WO2020191289A1 (en) * 2019-03-20 2020-09-24 Kindred Biosciences, Inc. Ngf antagonists for medical use

Also Published As

Publication number Publication date
WO2021212081A1 (en) 2021-10-21
CO2022014695A2 (es) 2022-10-21
CL2023003377A1 (es) 2024-04-19
KR20230005156A (ko) 2023-01-09
PE20230108A1 (es) 2023-01-25
MX2022012866A (es) 2022-11-08
CN115996949A (zh) 2023-04-21
US20230242635A1 (en) 2023-08-03
CL2022002857A1 (es) 2023-06-02
AU2021256056A1 (en) 2022-10-20
CA3175921A1 (en) 2021-10-21
IL297287A (en) 2022-12-01
BR112022020944A2 (pt) 2022-12-27
JP2023522029A (ja) 2023-05-26
TW202204403A (zh) 2022-02-01
EP4136106A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
CL2023003377A1 (es) Variantes de anticuerpos caninos
CL2023003376A1 (es) Variantes de anticuerpos felinos
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
EA202092847A1 (ru) Антитела к cd3 и их применение
EA201891694A1 (ru) Фармацевтическая композиция, содержащая конструкты биспецифических антител
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
ECSP23030271A (es) Variantes de anticuerpos caninos
CY1121678T1 (el) Νεο αντισωμα εναντι του ανθρωπινου υποδοχεα tslp
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
EA201992776A1 (ru) Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях
EA201991876A1 (ru) Антитела против фактора d и их применения
CY1125041T1 (el) Αντισωματα anti-il-22r
PE20230259A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
ECSP23030307A (es) Variantes de anticuerpos felinos
CL2023001781A1 (es) Mutaciones en regiones constantes de anticuerpos felinos
ECSP23057156A (es) Mutaciones en regiones constantes de anticuerpos caninos
CO2023007146A2 (es) Variantes de anticuerpos bovinos
MX2021007421A (es) Anticuerpo que se une a factor de crecimiento endotelial vascular (vegf) y a interleucina 1 beta (il-1beta) y metodos de uso.
TR202104726A2 (tr) Köfte form maki̇nasinda yeni̇li̇k
EA202091973A1 (ru) Конструкции слитых белков, содержащие анти-muc1 антитело и il-15
EA202191990A1 (ru) Состав терапевтического антитела
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
EA201992186A1 (ru) Антитела к par2 и пути их применения
EA202190255A1 (ru) Высокоаффинные, селективные в отношении изоформы ингибиторы tgf1 и их применение